Business Monitor International


Uganda Pharmaceuticals & Healthcare Report

Published 04 March 2014

  • 61 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Uganda Pharmaceuticals & Healthcare Report

BMI View: We do not expect Uganda's reliance on imported drugs to decrease, even though the government has been encouraging the domestic production of drugs. Additionally, export growth will be slow due to the limited capabilities of local pharmaceutical companies, which are unable to compete with the greater range of medicines made by multinational generic drugmakers.

Headline Expenditure Projections

  • Pharmaceuticals: UGX824.35bn (US$320mn) in 2013 to UGX924.83 (US$364mn) in 2014; +12.2% growth in local currency terms and +13.7% in US dollar terms.

  • Healthcare: UGX4,543.78bn (US$1.76bn) in 2013 to UGX4,923.36 (US$1.94bn) in 2014; 8.4% growth in local currency terms and 9.9% in US dollar terms.

Risk/Reward Ratings

In BMI's Q1214 Risk/Reward Ratings (RRRs), Uganda is ranked 23rd in the Middle East and Africa (MEA) region. While factors such as population growth and increasing healthcare needs will create a growing demand for pharmaceuticals, we note that a sizeable counterfeiting industry, poor healthcare funding, corruption, regulatory environment deficiencies and a number of other issues will conspire to keep Uganda in a similarly low position in the MEA matrix over the coming months.

Key Trends And Developments

  • In December 2013, it was reported that Swiss drugmaker Merck Serono is collaborating with Uganda's health ministry and Makerere university college of health science to launch a diabetes awareness campaign in the country, reports allAfrica. A study conducted by the Ugandan health ministry in 2011 revealed that, based on the number of doctor visits, the prevalence of diabetes has increased fivefold in the last 10 years. The campaign, which is titled 'Get informed- Get active- Get healthier', aims to reverse the increasing diabetes prevalence rate in the country by preventing or delaying the development of the disease.

  • According to the Ministry of Health in its Annual Health Sector Performance report, in FY2012/2013, government allocation to the...

Table of Contents

BMI Industry View
7
SWOT
9
Political
10
Economic
12
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Uganda Pharmaceutical Sales, Historical Data and Forecasts
16
Healthcare Market Forecast
17
Table: Uganda Healthcare Expenditure Trends, Historical Data and Forecasts
20
Table: Uganda Government Healthcare Expenditure Trends, Historical Data and Forecasts
20
Table: Uganda Private Healthcare Expenditure Trends, Historical Data and Forecasts
21
Macroeconomic Forecasts
22
Economic Analysis
22
Table: Uganda - Economic Activity
27
Industry Risk Reward Ratings
28
Middle East And Africa Risk/Reward Ratings
28
Uganda Risk/Reward Ratings
36
Rewards
36
Risks
36
Market Overview
38
Industry Trends And Developments
41
Epidemiology
41
Regulatory Development
43
Intellectual Property Issues
43
Supply Chain
44
Healthcare Provision
45
Recent Developments
46
Demographic Forecast
50
Table: Uganda's Population By Age Group, 1990-2020 ('000)
51
Table: Uganda's Population By Age Group, 1990-2020 (% of total)
52
Table: Uganda's Key Population Ratios, 1990-2020
53
Table: Uganda's Rural And Urban Population, 1990-2020
53
Glossary
54
Methodology
56
Pharmaceutical Expenditure Forecast Model
56
Healthcare Expenditure Forecast Model
56
Notes On Methodology
57
Risk/Reward Ratings Methodology
58
Ratings Overview
59
Table: Pharmaceutical Risk/Reward Ratings Indicators
59
Indicator Weightings
60

The Uganda Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Uganda Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Ugandan pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Uganda to test other views - a key input for successful budgeting and strategic business planning in the Ugandan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Ugandan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Uganda.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc